If this message does not display properly, please click here to launch your browser.
|
Based on our Pharmacor advisory service entitled Human Immunodeficiency Virus, Decision Resources is offering an exclusive analyst call entitled The Increasing Challenges of the Maturing HIV Drug Market: Will Gilead’s Quad or Merck’s Vicriviroc Be Able to Compete? Because this presentation will feature report updates, it is ONLY available to purchasers of this Pharmacor advisory service. Please contact us to learn how you can purchase this Pharmacor advisory service and attend the analyst call. The current availability of several efficacious, convenient and adequately safe options for the treatment of HIV has made physicians well-equipped to treat the disease. Owing to the availability of efficacious therapies, physicians now apply even greater scrutiny to emerging antiretroviral agents. As a result, drugs in development must demonstrate clear advantages over currently available therapies in order to be successful in the HIV drug market. Clinical trial data presented at last month’s 17th Conference on Retroviruses and Opportunistic Infections has elicited strong physician opinion regarding how the clinical performance of Gilead’s Quad and Merck’s vicriviroc will measure up against current treatment standards. Additionally, in an atmosphere that is increasingly characterized by stringent expectations of new therapies for treatment-naive and treatment-experienced HIV patients, it remains to be seen how the uptake of Quad and vicriviroc will impact the HIV drug market. This 15-minute analyst call, presented by Analyst Sylvia Eash, Ph.D., will answer the following questions:
Dr. Eash will conduct a live Q & A session after the presentation. Registration The Increasing Challenges of the Maturing HIV Drug Market: Will Gilead’s Quad or Merck’s Vicriviroc Be Able to Compete? March 16, 2010 at 10 a.m. U.S. Eastern Time, 3 p.m. Central European Time (Paris). To learn how you can purchase this Pharmacor advisory service and attend the analyst call, please contact us using the information below. In North America — Keith Rourke at 781-296-2656 or krourke@dresources.com |
|
||||
Terms of Use | Privacy Policy | Contact Us | Careers |
|||||
Sylvia Eash, Ph.D., is an anti-infectives and vaccines analyst for Decision Resources, where she offers extensive experience evaluating the clinical and commercial potential of current and emerging therapies and develops market forecasts. Dr. Eash is the author of several peer-reviewed primary literature and review articles, and she is a member of the American Society for Microbiology and the International Society of Neurovirology. She earned her doctoral degree from Brown University.